Daliresp Sales Pitch Draws FDA Letter After Forest Fails To Heed Advisory Comments
This article was originally published in The Pink Sheet Daily
The agency says the violation occurred despite FDA’s criticism of proposed promotional material for the respiratory drug and an ongoing corporate integrity agreement intended to block improper promotion.
You may also be interested in...
Primary care-focused pharma reports that preliminary voting results show former OSI executive Pierre Legault was elected to the Forest board, replacing long-time member and outgoing compensation committee Chairman Dan Goldwasser.
At a June 20 analyst meeting, Forest Labs discussed the potential for its respiratory pipeline, including the recently launched Daliresp and the yet-to-be approved aclidinium, which has a July PDUFA date.
A physician complained to FDA's "Bad Ad" program about a Forest Laboratories sales representative's off-label claims for the fibromyalgia drug Savella.